We are live on ! Find out more
OMC

OUP Management Company Portfolio holdings

AUM $44.5M
1-Year Est. Return 55.11%
This Fund
S&P 500
This Quarter Est. Return
-2.33%
1 Year Est. Return
+55.11%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$44.5M
AUM Growth
-$14.2M
Cap. Flow
-$12.3M
Cap. Flow %
-27.74%
Top 10 Hldgs %
99.57%
Holding
13
New
1
Increased
–
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
IMA
ImageneBio Inc
IMA
+$135K

Top Sells

Rank Stock Value
1
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTA
1
DELISTED
Centessa Pharmaceuticals
CNTA
$19M 42.74%
2,937,615
– –
JBIO
2
Jade Biosciences
JBIO
$1.27B
$8.19M 18.43%
17,250
– –
CYT
3
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$6.99M 15.71%
2,459,572
– –
PMVP icon
4
PMV Pharmaceuticals
PMVP
$71.5M
$6.07M 13.66%
989,232
– –
LENZ
5
LENZ Therapeutics
LENZ
$162M
$1.01M 2.27%
58,044
– –
RNAC icon
6
Cartesian Therapeutics
RNAC
$243M
$914K 2.06%
28,751
– –
VOR icon
7
Vor Biopharma
VOR
$980M
$794K 1.79%
18,736
– –
EFTR
8
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$615K 1.38%
41,028
– –
DTIL icon
9
Precision BioSciences
DTIL
$203M
$384K 0.86%
37,464
– –
SPRO icon
10
Spero Therapeutics
SPRO
$91.5M
$301K 0.68%
249,070
– –
IMA
11
ImageneBio Inc
IMA
$60.7M
$116K 0.26%
+2,236
New +$135K
QTTB icon
12
Q32 Bio
QTTB
$346M
$74.9K 0.17%
3,556
– –
DICE
13
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
– –
-268,346
Closed -$12.5M

Similar funds

JMF
Johnson Midwest Financial Glidden, Iowa $44.7M AUM 21.66% 1-Year Est. Return
AMC
Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return
MCAV
Meritech Capital Associates VI Palo Alto, California $45.3M AUM 4.6% 1-Year Est. Return
SIP
Scott Investment Partners Henley-On-Thames, United Kingdom $43.5M AUM 17.97% 1-Year Est. Return
KXA
KPCB XIV Associates Menlo Park, California $42.8M AUM 16.52% 1-Year Est. Return
WRCAI
West Rim Capital Associates II Lehi, Utah $46.8M AUM 11.72% 1-Year Est. Return
MAM
Must Asset Management Seoul, South Korea $40.9M AUM 22.53% 1-Year Est. Return
GIA
G2VP I Associates Portola Valley, California $48.2M AUM 37.59% 1-Year Est. Return

OUP Management Company's Q3 2023 Portfolio in Review

As of Q3 2023, OUP Management Company held 13 positions worth $44.5M, down 24% from $58.6M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

OUP Management Company withdrew a net $12.3M in Q3 2023, closing 1 position. Its most notable exit was DICE Therapeutics, Inc. Common Stock, an estimated $12.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, OUP Management Company opened a new position in ImageneBio Inc worth $116K.

  • OUP Management Company's largest Q3 2023 buy was ImageneBio Inc: 2,236 shares worth $116K.
  • OUP Management Company fully exited DICE Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $12.5M.
  • OUP Management Company's ten largest holdings make up 100% of its $44.5M portfolio in Q3 2023.
  • OUP Management Company opened 1 new position and closed 1 in Q3 2023.
  • OUP Management Company's portfolio value fell 24% quarter-over-quarter to $44.5M.

Based on OUP Management Company's 13F filing for Q3 2023, filed 9 Nov 2023.